Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Roivant Sciences Ltd (NQ: ROIV ) 11.13 -0.12 (-1.07%) Streaming Delayed Price Updated: 4:00 PM EDT, May 10, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 2,569,934 Open 11.38 Bid (Size) 11.09 (1) Ask (Size) 11.30 (4) Prev. Close 11.25 Today's Range 11.12 - 11.48 52wk Range 8.245 - 13.24 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare May 07, 2024 Investors concerned about broader market undulations may want to consider the resilience narrative of these biotech stocks to buy. Via InvestorPlace 3 Healthcare Stocks With the Potential to Triple Your Investment by 2026 May 01, 2024 Learn how these three healthcare stocks offer sharp opportunities in pharmaceuticals, healthcare services, and biotechnology. Via InvestorPlace Performance YTD -1.94% -1.94% 1 Month -0.36% -0.36% 3 Month +2.39% +2.39% 6 Month +22.98% +22.98% 1 Year +22.17% +22.17% More News Read More Critical Insights From Roivant Sciences Analyst Ratings: What You Need To Know April 22, 2024 Via Benzinga Vivek Ramaswamy-Founded Roivant's Anti-Inflammatory Drug Aces Mid-Stage Study April 02, 2024 Via Benzinga Roivant Sciences Stock Flirts With Breakout On 'Extremely Positive' Eye-Disease Study April 02, 2024 Via Investor's Business Daily Where Roivant Sciences Stands With Analysts March 25, 2024 Via Benzinga The Analyst Landscape: 4 Takes On Roivant Sciences February 14, 2024 Via Benzinga Roivant Sciences Earnings Preview February 12, 2024 Via Benzinga Assessing Roivant Sciences: Insights From 5 Financial Analysts January 02, 2024 Via Benzinga Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million April 02, 2024 From Roivant Sciences Via GlobeNewswire 10 Health Care Stocks Whale Activity In Today's Session March 29, 2024 Via Benzinga Solar Stocks Rally, Led By Sunrun, SolarEdge, Enphase March 27, 2024 Via Investor's Business Daily Analyst Ratings for Roivant Sciences December 12, 2023 Via Benzinga 5 Value Stocks In The Healthcare Sector February 19, 2024 Via Benzinga Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update February 13, 2024 From Roivant Sciences Via GlobeNewswire Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024 January 30, 2024 From Roivant Sciences Via GlobeNewswire Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space January 12, 2024 Via Investor's Business Daily Earnings Scheduled For February 13, 2024 February 13, 2024 Via Benzinga Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations January 10, 2024 Via Benzinga Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50% December 21, 2023 Via Benzinga Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease December 20, 2023 From Roivant Sciences Via GlobeNewswire FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session December 20, 2023 Via Benzinga Topics Stocks Exposures US Equities Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease December 14, 2023 From Roivant Sciences Via GlobeNewswire Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential November 28, 2023 From Roivant Sciences Via GlobeNewswire Why Is Vivek Ramaswamy-Founded Roivant Sciences Stock Trading Lower Today? November 27, 2023 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.